Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034840
Status:
COMPLETED
Last Update Posted:
2013-11-01
First Post:
2002-05-02
Brief Title:
Telmisartan vs Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Prospective Randomized Double-Blind Forced Titration Trial to Compare the Efficacy of MICARDIS Telmisartan 80 mg po Once Daily and Diovan Valsartan 160 mg po Once Daily Using Ambulatory Blood Pressure Monitoring ABPM in Patients With Mild to Moderate Hypertension After Missing One Dose
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives are to demonstrate that MICARDIS telmisartan is statistically superior to Diovan valsartan in reducing diastolic blood pressure DBP following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS is statistically superior to Diovan in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None